Financial liabilities - Kreos / Claret Financing (Details)
€ / shares in Units, € in Thousands, $ in Thousands |
|
|
|
|
|
|
|
|
|
|
|
|
1 Months Ended |
12 Months Ended |
145 Months Ended |
|
|
|
Dec. 23, 2025
EUR (€)
|
Nov. 25, 2025
EUR (€)
€ / shares
shares
|
Aug. 28, 2025
EUR (€)
shares
|
Aug. 08, 2025
EUR (€)
€ / shares
shares
|
Jul. 30, 2025
EUR (€)
shares
|
Dec. 31, 2024
EUR (€)
€ / shares
|
Jun. 21, 2024
EUR (€)
€ / shares
|
Jun. 21, 2024
USD ($)
|
Mar. 28, 2024
EUR (€)
€ / shares
|
Dec. 31, 2023
EUR (€)
€ / shares
|
Nov. 02, 2023
EUR (€)
€ / shares
shares
|
Aug. 22, 2023
EUR (€)
€ / shares
|
Aug. 20, 2023
EUR (€)
tranche
€ / shares
shares
|
Oct. 31, 2020
shares
|
Dec. 31, 2025
EUR (€)
€ / shares
shares
|
Dec. 31, 2024
EUR (€)
€ / shares
shares
|
Dec. 31, 2023
EUR (€)
€ / shares
|
Dec. 31, 2025
EUR (€)
€ / shares
|
Aug. 31, 2025
EUR (€)
|
Aug. 24, 2023
€ / shares
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Proceeds from borrowings |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 175,000
|
|
|
| Exercises of share warrants (in shares) | shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
464,309
|
|
4,000
|
|
|
|
|
| Exercises of the Kreos/Claret and other share warrants |
|
|
€ 11,531
|
|
€ 15,143
|
|
|
|
|
|
|
|
|
|
|
€ 45
|
|
|
|
|
| Interest expense on borrowings |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 95
|
85
|
€ 176
|
|
|
|
| Loss of extinguishment |
€ 3,838
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Financial liabilities, at fair value |
|
|
|
|
|
€ 162,256
|
|
|
|
€ 125,191
|
|
|
|
|
141,409
|
162,256
|
125,191
|
€ 141,409
|
|
|
| Non-cash changes: other fair value remeasurement |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
36,002
|
1,367
|
(3,198)
|
|
|
|
| Kreos & Claret bond loans |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Non-cash changes: other fair value remeasurement |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 0
|
€ 0
|
€ 0
|
|
|
|
| Market rate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Percentage of reasonably possible increase in unobservable input, liabilities |
|
|
|
|
|
|
|
|
|
|
|
|
1.00%
|
|
|
|
|
|
|
|
| Ordinary share price (in euro per share) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Amount of reasonably possible increase in unobservable input, liabilities (in euro per share) | € / shares |
|
|
|
|
|
€ 1
|
€ 1
|
|
€ 1
|
€ 1
|
€ 1
|
|
€ 1
|
|
€ 1
|
€ 1
|
€ 1
|
€ 1
|
|
€ 1
|
| Volatility |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Percentage of reasonably possible increase in unobservable input, liabilities |
|
|
|
|
|
1.00%
|
1.00%
|
|
1.00%
|
1.00%
|
1.00%
|
|
1.00%
|
|
1.00%
|
1.00%
|
1.00%
|
1.00%
|
|
1.00%
|
| Risk-free rate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Percentage of reasonably possible increase in unobservable input, liabilities |
|
|
|
|
|
1.00%
|
1.00%
|
|
1.00%
|
1.00%
|
1.00%
|
|
1.00%
|
|
1.00%
|
1.00%
|
1.00%
|
1.00%
|
|
1.00%
|
| Final redemption scenario probability |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Percentage of reasonably possible increase in unobservable input, liabilities |
|
|
|
|
|
|
5.00%
|
|
5.00%
|
|
|
|
|
|
10.00%
|
|
|
10.00%
|
|
|
| Discount rate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Percentage of reasonably possible increase in unobservable input, liabilities |
|
|
|
|
|
|
1.00%
|
|
1.00%
|
|
|
|
|
|
1.00%
|
|
|
1.00%
|
|
|
| 7-year expiry scenario probability |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Percentage of reasonably possible increase in unobservable input, liabilities |
|
|
|
|
|
5.00%
|
|
|
|
|
5.00%
|
|
5.00%
|
|
10.00%
|
5.00%
|
|
10.00%
|
|
|
| Kreos A & B BSA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Financial liabilities, at fair value |
|
|
|
|
|
|
|
|
|
|
|
|
€ 23,995
|
|
|
|
|
|
|
|
| Convertible loans notes |
|
|
|
|
|
|
|
|
|
|
|
|
25,000
|
|
|
|
|
|
|
|
| Carrying amount of the equity component |
|
|
|
|
|
|
|
|
|
|
|
|
€ 1,005
|
|
|
|
|
|
|
|
| Kreos A & B BSA | Market rate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Significant unobservable input, liabilities |
|
|
|
|
|
|
|
|
|
|
|
|
0.126
|
|
|
|
|
|
|
|
| Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, liabilities |
|
|
|
|
|
|
|
|
|
|
|
|
€ 624
|
|
|
|
|
|
|
|
| Kreos A & B BSA | Ordinary share price (in euro per share) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, assets |
|
|
|
|
|
|
|
|
|
|
|
|
197
|
|
|
|
|
|
|
|
| Kreos A & B BSA | Volatility |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, assets |
|
|
|
|
|
|
|
|
|
|
|
|
48
|
|
|
|
|
|
|
|
| Kreos A & B BSA | Risk-free rate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, assets |
|
|
|
|
|
|
|
|
|
|
|
|
64
|
|
|
|
|
|
|
|
| Kreos A & B BSA | 7-year expiry scenario probability |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, assets |
|
|
|
|
|
|
|
|
|
|
|
|
€ 64
|
|
|
|
|
|
|
|
| Kreos & Claret minimal return indemnifications | Ordinary share price (in euro per share) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Significant unobservable input, liabilities | € / shares |
|
|
|
|
|
|
12.94
|
|
13.40
|
|
|
|
|
|
|
|
|
|
|
|
| Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, assets |
|
|
|
|
|
|
€ (16)
|
|
€ (30)
|
|
|
|
|
|
€ (3)
|
|
|
|
|
|
| Kreos & Claret minimal return indemnifications | Volatility |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, assets |
|
|
|
|
|
|
€ 4
|
|
€ 4
|
|
|
|
|
|
(1)
|
|
|
|
|
|
| Kreos & Claret minimal return indemnifications | Volatility | Black Scholes Model |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Significant unobservable input, liabilities |
|
|
|
|
|
|
0.601
|
|
0.603
|
|
|
|
|
|
|
|
|
|
|
|
| Kreos & Claret minimal return indemnifications | Volatility | Monte Carlo Model |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Significant unobservable input, liabilities |
|
|
|
|
|
|
0.599
|
|
0.619
|
|
|
|
|
|
|
|
|
|
|
|
| Kreos & Claret minimal return indemnifications | Risk-free rate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, assets |
|
|
|
|
|
|
€ 8
|
|
€ (3)
|
|
|
|
|
|
(3)
|
|
|
|
|
|
| Kreos & Claret minimal return indemnifications | Risk-free rate | Black Scholes Model |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Significant unobservable input, liabilities |
|
|
|
|
|
|
0.030
|
|
0.026
|
|
|
|
|
|
|
|
|
|
|
|
| Kreos & Claret minimal return indemnifications | Risk-free rate | Monte Carlo Model |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Significant unobservable input, liabilities |
|
|
|
|
|
|
0.031
|
|
0.028
|
|
|
|
|
|
|
|
|
|
|
|
| Kreos & Claret minimal return indemnifications | Final redemption scenario probability |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, assets |
|
|
|
|
|
|
€ 46
|
|
€ 35
|
|
|
|
|
|
3
|
|
|
|
|
|
| Kreos & Claret minimal return indemnifications | Discount rate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, assets |
|
|
|
|
|
|
(13)
|
|
(53)
|
|
|
|
|
|
€ (82)
|
|
|
|
|
|
| Kreos A & B & C BSA | Ordinary share price (in euro per share) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, assets |
|
|
|
|
|
€ 350
|
|
|
|
€ 401
|
|
|
|
|
|
|
|
|
|
|
| Kreos A & B & C BSA | Volatility |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, assets |
|
|
|
|
|
37
|
|
|
|
96
|
|
|
|
|
|
|
|
|
|
|
| Kreos A & B & C BSA | Risk-free rate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, assets |
|
|
|
|
|
61
|
|
|
|
95
|
|
|
|
|
|
|
|
|
|
|
| Kreos A & B & C BSA | 7-year expiry scenario probability |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, assets |
|
|
|
|
|
75
|
|
|
|
76
|
|
|
|
|
|
|
|
|
|
|
| Kreos C BSA | Ordinary share price (in euro per share) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, assets |
|
|
|
|
|
|
|
|
|
|
€ 232
|
|
|
|
|
|
|
|
|
|
| Kreos C BSA | Volatility |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, assets |
|
|
|
|
|
|
|
|
|
|
28
|
|
|
|
|
|
|
|
|
|
| Kreos C BSA | Risk-free rate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, assets |
|
|
|
|
|
|
|
|
|
|
42
|
|
|
|
|
|
|
|
|
|
| Kreos C BSA | 7-year expiry scenario probability |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, assets |
|
|
|
|
|
|
|
|
|
|
36
|
|
|
|
|
|
|
|
|
|
| Kreos & Claret Financing, Tranche A,B and C | Kreos & Claret minimal return indemnifications |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value of other equity instruments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 3,620
|
|
| Kreos & Claret financing |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercises of share warrants (in shares) | shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
525,913
|
|
|
|
|
|
| Exercises of the Kreos/Claret and other share warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 33,768
|
|
|
|
|
|
| Kreos A & B BSA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value of other equity instruments |
|
|
|
|
|
243
|
|
|
|
920
|
|
€ 2,092
|
|
|
|
€ 243
|
€ 920
|
|
|
|
| Expiry scenario period, other equity instruments granted |
|
|
|
|
|
|
|
|
|
|
|
|
7 years
|
|
7 years
|
|
|
|
|
|
| Kreos C BSA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value of other equity instruments |
|
|
|
|
|
€ 923
|
|
|
|
€ 1,659
|
€ 1,493
|
|
|
|
|
€ 923
|
€ 1,659
|
|
|
|
| Expiry scenario period, other equity instruments granted |
|
|
|
|
|
|
|
|
|
|
7 years
|
|
|
|
|
|
|
|
|
|
| Kreos A & B & C BSA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Expiry scenario period, other equity instruments granted |
|
|
|
|
|
7 years
|
|
|
|
7 years
|
|
|
|
|
|
|
|
|
|
|
| Kreos & Claret financing |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Borrowings, maximum borrowing capacity |
|
|
|
|
|
|
|
|
|
|
|
|
€ 75,000
|
|
|
|
|
|
|
|
| Borrowings, number of tranches | tranche |
|
|
|
|
|
|
|
|
|
|
|
|
3
|
|
|
|
|
|
|
|
| Borrowings, maximum borrowing capacity per tranche |
|
|
|
|
|
|
|
|
|
|
|
|
€ 25,000
|
|
|
|
|
|
|
|
| Other share warrants, exercise period |
|
|
|
|
|
|
|
|
|
|
|
|
7 years
|
|
|
|
|
|
|
|
| Kreos & Claret financing | Kreos A & B BSA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Other share warrants, subscripion price per share (in euro per share) | € / shares |
|
|
|
|
|
|
|
|
|
|
|
|
€ 1.00
|
|
|
|
|
|
|
|
| Number of warrants granted (in shares) | shares |
|
|
|
|
|
|
|
|
|
|
|
|
214,198
|
|
|
|
|
|
|
|
| Exercise price, other equity instruments granted (in euro per share) | € / shares |
|
|
|
|
|
|
|
|
|
|
|
|
€ 18.6744
|
|
|
|
|
|
|
|
| Exercise price, percentage of premium |
|
|
|
|
|
|
|
|
|
|
|
|
10.00%
|
|
|
|
|
|
|
|
| Kreos & Claret financing | Kreos C BSA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of warrants granted (in shares) | shares |
|
|
|
|
|
|
|
|
|
|
405,832
|
|
|
|
|
|
|
|
|
|
| Exercise price, other equity instruments granted (in euro per share) | € / shares |
|
|
|
|
|
|
|
|
|
|
€ 9.86
|
|
|
|
|
|
|
|
|
|
| Exercise price, percentage of 15-day WVAP |
|
|
|
|
|
|
|
|
|
|
110.00%
|
|
|
|
|
|
|
|
|
|
| Issuance of other share warrants |
|
|
|
|
|
|
|
|
|
|
€ 4,000
|
|
|
|
|
|
|
|
|
|
| Number of instruments granted, percentage exercisable immediately |
|
|
|
|
|
|
|
|
|
|
50.00%
|
|
|
|
|
|
|
|
|
|
| Number of instruments granted, remaining percentage exercisable |
|
|
|
|
|
|
|
|
|
|
50.00%
|
|
|
|
|
|
|
|
|
|
| Kreos & Claret convertible notes (OCABSA) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Proceeds from borrowings |
|
|
|
|
|
|
|
|
|
|
|
€ 25,000
|
|
|
|
|
|
|
|
|
| Borrowings, fixed conversion price (in euro per share) | € / shares |
|
|
|
|
|
|
|
|
|
|
|
€ 21.2209
|
|
|
|
|
|
|
|
|
| Borrowings, interest rate |
|
|
|
|
|
|
|
|
|
|
|
|
9.00%
|
|
|
|
|
|
|
|
| Borrowings, early repayment, discount rate |
|
|
|
|
|
|
|
|
|
|
|
|
4.00%
|
|
|
|
|
|
|
|
| Borrowings, exit fee percentage |
|
|
|
|
|
|
|
|
|
|
|
|
8.00%
|
|
|
|
|
|
|
|
| Kreos & Claret convertible notes (OCABSA) | Ordinary shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Borrowings, fixed conversion price (in euro per share) | € / shares |
|
€ 21.2209
|
|
€ 21.2209
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Conversion of convertible instruments (in shares) | shares |
|
392,695
|
|
785,389
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Increase (decrease) through conversion of convertible instruments, equity |
|
€ 8,296
|
|
€ 16,058
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Kreos & Claret financing, tranche B |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Proceeds from borrowings |
|
|
|
|
|
|
|
|
€ 25,000
|
|
|
|
|
|
|
|
|
|
|
|
| Borrowings, debt-to-market capitalization ratio |
|
|
|
|
|
|
|
|
10.00%
|
|
|
|
|
|
|
|
|
|
|
|
| Kreos & Claret financing, tranche C |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Borrowings, maximum borrowing capacity |
|
|
|
|
|
|
25,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Proceeds from borrowings |
|
|
|
|
|
|
€ 25,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Borrowings, debt-to-market capitalization ratio |
|
|
|
|
|
|
10.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Performance conditions, minimum financing | $ |
|
|
|
|
|
|
|
$ 125,000
|
|
|
|
|
|
|
|
|
|
|
|
|
| Kreos & Claret financing, tranche B and C |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Borrowings, number of tranches | tranche |
|
|
|
|
|
|
|
|
|
|
|
|
2
|
|
|
|
|
|
|
|
| Borrowings, early repayment, discount rate |
|
|
|
|
|
|
|
|
|
|
|
|
4.00%
|
|
|
|
|
|
|
|
| Borrowings, exit fee percentage |
|
|
|
|
|
|
|
|
|
|
|
|
6.00%
|
|
|
|
|
|
|
|
| Borrowings, discount rate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4.00%
|
|
|
4.00%
|
|
|
| Kreos & Claret financing, tranche B and C | European Central Bank base rate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Borrowings, adjustment to interest rate basis |
|
|
|
|
|
7.50%
|
|
|
|
|
|
|
7.50%
|
|
|
7.50%
|
|
|
|
|
| Kreos & Claret financing, tranche B and C | European Central Bank base rate | Bottom of range |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Borrowings, interest rate basis |
|
|
|
|
|
2.50%
|
|
|
|
|
|
|
2.50%
|
|
|
2.50%
|
|
|
|
|
| Kreos & Claret financing, tranche B and C | European Central Bank base rate | Top of range |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Borrowings, interest rate basis |
|
|
|
|
|
4.00%
|
|
|
|
|
|
|
4.00%
|
|
|
4.00%
|
|
|
|
|
| Kreos 1 bond loans |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Repayments of bond loans |
|
|
|
|
|
|
|
|
|
|
|
€ 7,661
|
|
|
|
|
|
|
|
|
| Kreos A & B & C BSA | Kreos & Claret financing |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of warrants repurchased (in shares) | shares |
|
|
|
|
94,117
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Kreos A & B & C BSA | Ordinary shares | Kreos & Claret financing |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercises of share warrants (in shares) | shares |
|
|
206,662
|
|
319,251
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercises of the Kreos/Claret and other share warrants |
|
|
€ 14,198
|
|
€ 19,570
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Kreos/Claret financing B and C |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Repayments of borrowings, classified as financing activities |
33,823
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Borrowings |
29,903
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Deposit paid, borrowing |
€ 1,081
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Borrowings, discount rate |
4.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Interest expense on borrowings |
€ 2,001
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Borrowings, exit fee amount |
3,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Notional amount |
€ 29,985
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|